Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.